跳至主要内容
临床试验/CTRI/2024/10/076011
CTRI/2024/10/076011尚未招募4 期

To evaluate the clinical efficacy of Dexmedetomidine as an adjuvant to Ropivacaine in USG guided suprainguinal fascia iliaca block for peri-operative analgesia in patients of trochanteric fractures.

Shweta Bhatia1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年11月8日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
VAS at rest and on passive external rotation of the limb 20 minutes after the block and EOSP.

研究概览

简要总结

we are comparing the efficacy of dexmedetomidine0.5micrograms / kg  and 0.25%ropivacaine with 0.25 %ropivacaine in USG guided suprainguinal fascia iliaca block in patients of trochanter fractures for peri-operative pain management .the block will be given in preoperative room  and after 20 minutes pain score will be noted and ease of positioning for spinal will be noted . the pain score and vitals will be recorded in the post operative period

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant, Investigator and Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 70.00 Year(s)(—)
性别
All

入选标准

  • ASA PS I TO III
  • BMI 18.5 -29.9
  • Patients with trochanteric fracture who will be scheduled to undergo fixation of fracture ( intertrochanteric and subtrochanteric ) under spinal anaesthesia.

排除标准

  • patients refusal to participate in study
  • patients with anatomical spinal deformities.
  • patient with bleeding disorders and raised intracranial pressure.
  • patient with local infection at the sites where needle for spinal is to be inserted and altered anatomy like inguinal hernia, and femoral artery graft.
  • patients with dysrhythmias.
  • patients allergic to study drugs.
  • patients on anticoagulants, polytrauma.
  • failure of soinal anesthesia.
  • trochanteric femoral fractures associated with other fractures .

结局指标

主要结局

VAS at rest and on passive external rotation of the limb 20 minutes after the block and EOSP.

时间窗: 20 minutes

次要结局

  • total duration of analgesia(amount of tramadol used)

研究者

发起方
Shweta Bhatia
申办方类型
Other [self]
责任方
Principal Investigator
主要研究者

Dr Shweta Bhatia

DR RPGMC TANDA Kangra HIMACHAL PRADESH

研究点 (1)

Loading locations...

相似试验